Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P302)

NCT03841773 is registered in ClinicalTrials.gov with Tonix Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03841773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03841773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P302)
Lead sponsor
Tonix Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
March 7, 2019
Completion date
April 24, 2020
Enrollment
192 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

ptsd